Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Feb 05, 2024 8:10am
47 Views
Post# 35862562

RE:RE:RE:What happens if Oast does not agree?

RE:RE:RE:What happens if Oast does not agree?When your reputation is in the mud and have a track record of shareholder destruction, you better change your company name from AEZS first than hope you can pull the wool over new investors.

But yes the "biggest biotech" disaster in decades will make it hard for a biopharma cash burning company to raise funds on an old tired drug like Macrilen. 

With CEAPRO which had (has) a stable base business that can fund it's pipeline and with potential game changing results for AV due in the fall, in the hands of a capable new CEO, it would be much easier to raise funds on its own.
<< Previous
Bullboard Posts
Next >>